Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07431086 · ClinicalTrials.gov registry record · Phase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT07431086 is a Phase 2 study that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 120 participants.
The verdict
NCT07431086, a Phase 2 study, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study will test how safe and effective the study drug works compared to placebo in people who are overweight or obese but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much the study drug is in the blood at different times * How well the study drug works * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
Interventions
- DRUG Placebo
- DRUG Olatorepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2026-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07431086
The ClinicalTrials.gov registry entry for NCT07431086 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07431086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07431086 about?
NCT07431086 is a clinical study titled "Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US". This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study will test how safe and ...
What is the current status of trial NCT07431086?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-03-16. Estimated completion is 2026-12-18.
What interventions are being tested in trial NCT07431086?
The interventions under investigation include: Placebo (DRUG), Olatorepatide (DRUG).
Who is sponsoring clinical trial NCT07431086?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.